Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146538 | 0.87 | GCK (0.59) | GCKKCNH2 | |
| SCHEMBL1427182 | 0.87 | GCK (0.46) | GCKKCNH2RARARARBRARG | |
| SCHEMBL1427233 | 0.86 | GCK (0.63) | GCKKCNH2 | |
| SCHEMBL2906565 | 0.85 | GCK (0.48) | GCKKCNH2 | |
| SCHEMBL3303035 | 0.84 | GCK (0.67) | GCKKCNH2RARARARBRARG | |
| SCHEMBL2901755 | 0.76 | GCK (0.69) | GCKKCNH2 | |
| SCHEMBL3342969 | 0.76 | GCK (0.54) | GCKKCNH2 | |
| SCHEMBL2667095 | 0.76 | GCK (0.54) | GCKKCNH2 | |
| SCHEMBL2899089 | 0.76 | GCK (0.69) | GCKKCNH2 | |
| SCHEMBL1427114 | 0.76 | GCK (0.54) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094009-A1 | NOVEL CRYSTALLINE COMPOUND USEFUL AS GLK ACTIVATOR | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-7696191-B2 | Crystalline compound | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| EP-2121666-A1 | NOVEL CRYSTALLINE COMPOUND USEFUL AS GLK ACTIVATOR | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080153800-A1 | NOVEL CRYSTALLINE COMPOUND | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008075073-A1 | NOVEL CRYSTALLINE COMPOUND USEFUL AS GLK ACTIVATOR | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153800-A1 | NOVEL CRYSTALLINE COMPOUND | GCK, GCKR, GK | GCK 1/4885KCNH2 621/4885RARA 3225/4885 |
| US-20100094009-A1 | NOVEL CRYSTALLINE COMPOUND USEFUL AS GLK ACTIVATOR | GCK, GCKR, GK | GCK 1/4885KCNH2 679/4885RARA 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.